Homology Medicines, Inc. (NASDAQ:FIXX) Receives $8.51 Average Target Price from Analysts

Shares of Homology Medicines, Inc. (NASDAQ:FIXX – Get Rating) have been assigned an average recommendation of “Moderate Buy” from the eight research firms that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $8.51.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Homology Medicines in a report on Thursday.

Homology Medicines Stock Performance

Shares of NASDAQ:FIXX opened at $0.95 on Thursday. The firm has a market cap of $54.80 million, a PE ratio of -8.64 and a beta of -0.01. The firm’s 50 day simple moving average is $1.47 and its 200-day simple moving average is $1.54. Homology Medicines has a one year low of $0.95 and a one year high of $3.57.

Institutional Trading of Homology Medicines

Several hedge funds have recently made changes to their positions in the company. Marshall Wace LLP increased its holdings in Homology Medicines by 40.4% during the 3rd quarter. Marshall Wace LLP now owns 30,175 shares of the company’s stock valued at $48,000 after acquiring an additional 8,689 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Homology Medicines by 6.3% during the second quarter. Renaissance Technologies LLC now owns 248,800 shares of the company’s stock worth $490,000 after buying an additional 14,800 shares in the last quarter. Bank of America Corp DE grew its holdings in shares of Homology Medicines by 4.5% during the fourth quarter. Bank of America Corp DE now owns 361,621 shares of the company’s stock worth $456,000 after buying an additional 15,467 shares in the last quarter. Raymond James & Associates purchased a new stake in shares of Homology Medicines during the first quarter worth about $51,000. Finally, Mirabella Financial Services LLP purchased a new stake in shares of Homology Medicines during the first quarter worth about $53,000. Institutional investors and hedge funds own 40.73% of the company’s stock.

About Homology Medicines

(Get Rating)

Homology Medicines, Inc is a clinical-stage genetic medicines company, which engages in the translation of proprietary gene editing and gene therapy technology into novel treatments for patients with rare genetic diseases. The company was founded in March 2015 and is headquartered in Bedford, MA.